Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Dr Reddy’s Laboratories ( (RDY) ) has issued an update.
Dr. Reddy’s Laboratories announced its financial results for the quarter and year ending March 31, 2025, on May 9, 2025. The company reported audited financial results under both International Financial Reporting Standards (IFRS) and Indian Accounting Standards (Ind AS). The Board of Directors approved a final dividend of Rs. 8 per equity share and re-appointed Mr. G V Prasad as Co-Chairman and Managing Director for another five years starting January 30, 2026. Additionally, the company appointed Makarand M. Joshi & Co. as Secretarial Auditors for a five-year term. These developments reflect the company’s continued focus on financial transparency and leadership stability, which are likely to reinforce its strong position in the pharmaceutical industry.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a multinational pharmaceutical company based in Hyderabad, India. It operates in the pharmaceutical industry, focusing on the development and manufacturing of generic medications, active pharmaceutical ingredients, and over-the-counter drugs. The company is known for its emphasis on research, innovation, and high standards of corporate governance, positioning itself as a leader in the global pharmaceutical market.
Average Trading Volume: 2,157,442
Technical Sentiment Signal: Sell
Current Market Cap: $11.26B
For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.